港股医药板块表现强势，关注恒生创新药ETF（159316）、港股通医药ETF（513200）等投资机会

Group 1 - The core viewpoint of the news highlights the positive performance of various healthcare indices, with the Hang Seng Hong Kong Stock Connect Innovative Drug Index rising by 1.0% and the overall healthcare sector indices showing upward trends [1][2][3] - The Hang Seng Innovative Drug ETF (159316) has seen a net inflow of funds for five consecutive trading days, reaching a record size of over 1.2 billion yuan [1][2] - The indices mentioned focus on leading companies in the pharmaceutical and biotechnology sectors, with specific indices tracking innovative drug companies in both Hong Kong and A-shares [2][3] Group 2 - The rolling price-to-earnings (P/E) ratio for the Hang Seng Hong Kong Stock Connect Innovative Drug Index is reported at 57.4 times, while the P/E ratio for the Hong Kong Stock Connect Medical and Health Comprehensive Index stands at 31.6 times [2][3] - The A-share Innovative Drug Industry Index has a rolling P/E ratio of 52.6 times, indicating a strong valuation in the innovative drug sector [2] - The rolling P/E ratio for the Biotech Theme Index is noted at 54.9 times, reflecting the valuation dynamics within the biotech industry [2]